Clinical trials of direct thrombin inhibitors in acute ischaemic syndromes

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 364-366

  White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRUDIN; HIRULOG; THROMBIN; THROMBIN INHIBITOR;

ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; HEART MUSCLE ISCHEMIA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBOSIS;

EID: 0030857055     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657553     Document Type: Conference Paper

References (17)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
2. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial. Circulation 1996; 93: 870-8.
3. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
4. Antman EM. Antiplatelet/antithrombotic agents. Presented at Plenary Seminar, Joint AHA/European Society of Cardiology Symposium: Contemporary Strategies for Acute Myocardial Infarction. American Heart Association, 68th Scientific Sessions, Anaheim, California, November 1995. Unpublished.
5. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
7. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-20.
8. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657-65.
9. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989; 55: 635-43.
10. Lee CD, Mann KG. Activation/inactivation of human coagulation factor V by plasmin. Blood 1989; 73: 185-90.
11. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-25.
12. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction: the importance of early reperfusion. Circulation 1994; 90: 2658-65.
13. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923-8.
14. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994; 23: 993-1003.
15. Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van de Werf F, for the GUSTO 2A Investigators. Effects of heparin and hirudin (CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction [abstract]. Circulation 1995;92 Suppl I:I-740.
16. Gold HK, Torres FW, Garabedian HD, Werner W, Jang I, Khan A, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993; 21: 1039-47.
17. White HD, Aylward PE, Frey M, Adgey J, Nair R, Hillis WS, et al. A randomized, double-blind comparison of Hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Submitted for publication.